JP2016538254A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016538254A5 JP2016538254A5 JP2016522050A JP2016522050A JP2016538254A5 JP 2016538254 A5 JP2016538254 A5 JP 2016538254A5 JP 2016522050 A JP2016522050 A JP 2016522050A JP 2016522050 A JP2016522050 A JP 2016522050A JP 2016538254 A5 JP2016538254 A5 JP 2016538254A5
- Authority
- JP
- Japan
- Prior art keywords
- tyrosine
- methyl
- amino
- propanoate
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 79
- 229940122110 Tyrosine hydroxylase inhibitor Drugs 0.000 claims description 54
- 150000003667 tyrosine derivatives Chemical group 0.000 claims description 54
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 26
- VXYFARNRGZWHTJ-SBSPUUFOSA-N hydron;methyl (2r)-2-amino-3-(4-hydroxyphenyl)propanoate;chloride Chemical compound Cl.COC(=O)[C@H](N)CC1=CC=C(O)C=C1 VXYFARNRGZWHTJ-SBSPUUFOSA-N 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 claims description 16
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 12
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 12
- 208000024908 graft versus host disease Diseases 0.000 claims description 12
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 11
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 10
- -1 dodecylnonoxy Chemical group 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- NHTGHBARYWONDQ-JTQLQIEISA-N L-α-methyl-Tyrosine Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C=C1 NHTGHBARYWONDQ-JTQLQIEISA-N 0.000 claims description 8
- NHTGHBARYWONDQ-SNVBAGLBSA-N (2r)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid Chemical compound OC(=O)[C@@](N)(C)CC1=CC=C(O)C=C1 NHTGHBARYWONDQ-SNVBAGLBSA-N 0.000 claims description 7
- JZKXXXDKRQWDET-UHFFFAOYSA-N 2-azaniumyl-3-(3-hydroxyphenyl)propanoate Chemical compound OC(=O)C(N)CC1=CC=CC(O)=C1 JZKXXXDKRQWDET-UHFFFAOYSA-N 0.000 claims description 6
- WRFPVMFCRNYQNR-UHFFFAOYSA-N 2-hydroxyphenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1O WRFPVMFCRNYQNR-UHFFFAOYSA-N 0.000 claims description 6
- ACWBBAGYTKWBCD-ZETCQYMHSA-N 3-chloro-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(Cl)=C1 ACWBBAGYTKWBCD-ZETCQYMHSA-N 0.000 claims description 6
- FBTSQILOGYXGMD-LURJTMIESA-N 3-nitro-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C([N+]([O-])=O)=C1 FBTSQILOGYXGMD-LURJTMIESA-N 0.000 claims description 6
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 6
- 206010003805 Autism Diseases 0.000 claims description 6
- 208000020706 Autistic disease Diseases 0.000 claims description 6
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 6
- 201000004624 Dermatitis Diseases 0.000 claims description 6
- 208000001640 Fibromyalgia Diseases 0.000 claims description 6
- 208000010718 Multiple Organ Failure Diseases 0.000 claims description 6
- 206010033645 Pancreatitis Diseases 0.000 claims description 6
- 206010033647 Pancreatitis acute Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical group N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 6
- 201000003229 acute pancreatitis Diseases 0.000 claims description 6
- 206010003246 arthritis Diseases 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 6
- 208000010668 atopic eczema Diseases 0.000 claims description 6
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 6
- 229960000623 carbamazepine Drugs 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 208000037902 enteropathy Diseases 0.000 claims description 6
- GITKQXFBNJTMRP-QRPNPIFTSA-N ethyl (2s)-2-amino-3-(4-hydroxy-3-nitrophenyl)propanoate;hydrochloride Chemical compound Cl.CCOC(=O)[C@@H](N)CC1=CC=C(O)C([N+]([O-])=O)=C1 GITKQXFBNJTMRP-QRPNPIFTSA-N 0.000 claims description 6
- BQULAXAVRFIAHN-UHFFFAOYSA-N ethyl 2-amino-3-(4-hydroxyphenyl)propanoate;hydron;chloride Chemical compound Cl.CCOC(=O)C(N)CC1=CC=C(O)C=C1 BQULAXAVRFIAHN-UHFFFAOYSA-N 0.000 claims description 6
- 208000028774 intestinal disease Diseases 0.000 claims description 6
- BPKBTKQFMPZVNO-SSDOTTSWSA-N methyl (2r)-2-amino-3-(2,6-dichloro-3-hydroxy-4-methoxyphenyl)propanoate Chemical compound COC(=O)[C@H](N)CC1=C(Cl)C=C(OC)C(O)=C1Cl BPKBTKQFMPZVNO-SSDOTTSWSA-N 0.000 claims description 6
- WOOVWLVXVNIALE-SSDOTTSWSA-N methyl (2r)-2-amino-3-(2-chloro-3-hydroxy-4-methoxyphenyl)propanoate Chemical compound COC(=O)[C@H](N)CC1=CC=C(OC)C(O)=C1Cl WOOVWLVXVNIALE-SSDOTTSWSA-N 0.000 claims description 6
- URTGFUAPYILQFF-SECBINFHSA-N methyl (2r)-2-amino-3-(2-chloro-4-hydroxyphenyl)propanoate Chemical group COC(=O)[C@H](N)CC1=CC=C(O)C=C1Cl URTGFUAPYILQFF-SECBINFHSA-N 0.000 claims description 6
- JRBGZVHYLIYGFT-SECBINFHSA-N methyl (2r)-2-amino-3-(3-chloro-4,5-dimethoxyphenyl)propanoate Chemical compound COC(=O)[C@H](N)CC1=CC(Cl)=C(OC)C(OC)=C1 JRBGZVHYLIYGFT-SECBINFHSA-N 0.000 claims description 6
- YBYSJBGPVNPDJO-MRVPVSSYSA-N methyl (2r)-2-amino-3-(3-chloro-4-hydroxy-5-methoxyphenyl)propanoate Chemical compound COC(=O)[C@H](N)CC1=CC(Cl)=C(O)C(OC)=C1 YBYSJBGPVNPDJO-MRVPVSSYSA-N 0.000 claims description 6
- QUBSTZJVDZUTFR-SECBINFHSA-N methyl (2r)-2-amino-3-(3-chloro-4-methoxyphenyl)propanoate Chemical compound COC(=O)[C@H](N)CC1=CC=C(OC)C(Cl)=C1 QUBSTZJVDZUTFR-SECBINFHSA-N 0.000 claims description 6
- ZSDSFDQBWLLWEN-MRVPVSSYSA-N methyl (2r)-2-amino-3-(3-chloro-5-fluoro-4-hydroxyphenyl)propanoate Chemical compound COC(=O)[C@H](N)CC1=CC(F)=C(O)C(Cl)=C1 ZSDSFDQBWLLWEN-MRVPVSSYSA-N 0.000 claims description 6
- MWZPENIJLUWBSY-SECBINFHSA-N methyl (2r)-2-amino-3-(4-hydroxyphenyl)propanoate Chemical compound COC(=O)[C@H](N)CC1=CC=C(O)C=C1 MWZPENIJLUWBSY-SECBINFHSA-N 0.000 claims description 6
- ZXXAWWHROSUPMV-MRXNPFEDSA-N methyl (2r)-2-amino-3-[4-[(2-chloro-6-fluorophenyl)methoxy]phenyl]propanoate Chemical compound C1=CC(C[C@@H](N)C(=O)OC)=CC=C1OCC1=C(F)C=CC=C1Cl ZXXAWWHROSUPMV-MRXNPFEDSA-N 0.000 claims description 6
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 6
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 6
- 230000007863 steatosis Effects 0.000 claims description 6
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 6
- 229960000604 valproic acid Drugs 0.000 claims description 6
- NHTGHBARYWONDQ-UHFFFAOYSA-N (+-)-α-methyl-tyrosine Chemical compound OC(=O)C(N)(C)CC1=CC=C(O)C=C1 NHTGHBARYWONDQ-UHFFFAOYSA-N 0.000 claims description 5
- 208000030507 AIDS Diseases 0.000 claims description 5
- 206010009208 Cirrhosis alcoholic Diseases 0.000 claims description 5
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 5
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims description 5
- 230000007613 environmental effect Effects 0.000 claims description 5
- BICWDWHXTTXTDU-MRVPVSSYSA-N methyl (2r)-2-amino-3-(2,6-dichloro-3,4-dimethoxyphenyl)propanoate Chemical compound COC(=O)[C@H](N)CC1=C(Cl)C=C(OC)C(OC)=C1Cl BICWDWHXTTXTDU-MRVPVSSYSA-N 0.000 claims description 5
- KWTIOVPQMRSIJF-MRVPVSSYSA-N methyl (2r)-2-amino-3-(3-chloro-4-hydroxyphenyl)propanoate Chemical compound COC(=O)[C@H](N)CC1=CC=C(O)C(Cl)=C1 KWTIOVPQMRSIJF-MRVPVSSYSA-N 0.000 claims description 5
- 229960004441 tyrosine Drugs 0.000 claims description 5
- OOTFAHIVGAQXOL-LBPRGKRZSA-N (2,5-dioxopyrrolidin-1-yl) (2s)-3-(4-hydroxy-3,5-diiodophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound C([C@H](NC(=O)OC(C)(C)C)C(=O)ON1C(CCC1=O)=O)C1=CC(I)=C(O)C(I)=C1 OOTFAHIVGAQXOL-LBPRGKRZSA-N 0.000 claims description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 4
- 239000005642 Oleic acid Substances 0.000 claims description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- JZUZJVFERQWLNC-FQEVSTJZSA-N fmoc-3-nitro-l-tyrosine Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=C(O)C([N+]([O-])=O)=C1 JZUZJVFERQWLNC-FQEVSTJZSA-N 0.000 claims description 4
- 201000001421 hyperglycemia Diseases 0.000 claims description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 4
- ATVDFEWFLSSKBM-MRVPVSSYSA-N methyl (2r)-2-amino-3-(2-chloro-3,4-dimethoxyphenyl)propanoate Chemical compound COC(=O)[C@H](N)CC1=CC=C(OC)C(OC)=C1Cl ATVDFEWFLSSKBM-MRVPVSSYSA-N 0.000 claims description 4
- RAXWZGMSMQUDTR-UHFFFAOYSA-N methyl 2-amino-3-(4-hydroxy-3,5-diiodophenyl)propanoate;hydrochloride Chemical compound Cl.COC(=O)C(N)CC1=CC(I)=C(O)C(I)=C1 RAXWZGMSMQUDTR-UHFFFAOYSA-N 0.000 claims description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 3
- 230000000968 intestinal effect Effects 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- CNBUSIJNWNXLQQ-NSHDSACASA-N (2s)-3-(4-hydroxyphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CNBUSIJNWNXLQQ-NSHDSACASA-N 0.000 claims description 2
- 208000034486 Multi-organ failure Diseases 0.000 claims description 2
- 230000003870 intestinal permeability Effects 0.000 claims description 2
- 239000005022 packaging material Substances 0.000 claims description 2
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 21
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 3
- 201000002772 Kwashiorkor Diseases 0.000 claims 3
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 claims 2
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims 2
- SWZCTMTWRHEBIN-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=C(O)C=C1 SWZCTMTWRHEBIN-QFIPXVFZSA-N 0.000 claims 1
- WWYDYZMNFQIYPT-UHFFFAOYSA-L 2-phenylpropanedioate Chemical compound [O-]C(=O)C(C([O-])=O)C1=CC=CC=C1 WWYDYZMNFQIYPT-UHFFFAOYSA-L 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- VXYFARNRGZWHTJ-UHFFFAOYSA-N [3-(4-hydroxyphenyl)-1-methoxy-1-oxopropan-2-yl]azanium;chloride Chemical compound Cl.COC(=O)C(N)CC1=CC=C(O)C=C1 VXYFARNRGZWHTJ-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 3
- IAKTVIKWSYAWIG-UHFFFAOYSA-N 2-nonoxytetradecane-1,2-diol Chemical compound C(CCCCCCCCCCC)C(CO)(OCCCCCCCCC)O IAKTVIKWSYAWIG-UHFFFAOYSA-N 0.000 description 2
- 229930195709 D-tyrosine Natural products 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- RAXWZGMSMQUDTR-QRPNPIFTSA-N methyl (2s)-2-amino-3-(4-hydroxy-3,5-diiodophenyl)propanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CC1=CC(I)=C(O)C(I)=C1 RAXWZGMSMQUDTR-QRPNPIFTSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361894261P | 2013-10-22 | 2013-10-22 | |
| US61/894,261 | 2013-10-22 | ||
| US14/062,165 | 2013-10-24 | ||
| US14/062,165 US20150111878A1 (en) | 2013-10-22 | 2013-10-24 | Compositions and methods for treating intestinal hyperpermeability |
| PCT/US2014/061590 WO2015061328A2 (en) | 2013-10-22 | 2014-10-21 | Compositions and methods for treating intestinal hyperpermeability |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019119837A Division JP2019203003A (ja) | 2013-10-22 | 2019-06-27 | 腸透過性亢進を治療するための組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016538254A JP2016538254A (ja) | 2016-12-08 |
| JP2016538254A5 true JP2016538254A5 (enExample) | 2017-12-07 |
Family
ID=52826698
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016522050A Pending JP2016538254A (ja) | 2013-10-22 | 2014-10-21 | 腸透過性亢進を治療するための組成物及び方法 |
| JP2019119837A Pending JP2019203003A (ja) | 2013-10-22 | 2019-06-27 | 腸透過性亢進を治療するための組成物及び方法 |
| JP2020155074A Pending JP2021001194A (ja) | 2013-10-22 | 2020-09-16 | 腸透過性亢進を治療するための組成物及び方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019119837A Pending JP2019203003A (ja) | 2013-10-22 | 2019-06-27 | 腸透過性亢進を治療するための組成物及び方法 |
| JP2020155074A Pending JP2021001194A (ja) | 2013-10-22 | 2020-09-16 | 腸透過性亢進を治療するための組成物及び方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150111878A1 (enExample) |
| EP (3) | EP3238707B1 (enExample) |
| JP (3) | JP2016538254A (enExample) |
| KR (1) | KR20160093000A (enExample) |
| CN (2) | CN113893239A (enExample) |
| AU (2) | AU2014340303B2 (enExample) |
| CA (1) | CA2925324A1 (enExample) |
| DK (1) | DK3238707T3 (enExample) |
| ES (1) | ES2865505T3 (enExample) |
| IL (2) | IL244707B (enExample) |
| MX (1) | MX2016004920A (enExample) |
| PH (3) | PH12016500581A1 (enExample) |
| PL (1) | PL3238707T3 (enExample) |
| PT (1) | PT3238707T (enExample) |
| RS (1) | RS61806B1 (enExample) |
| WO (1) | WO2015061328A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10751313B2 (en) | 2013-10-22 | 2020-08-25 | Yamo Pharmaceuticals Llc | Compositions and methods for treating autism |
| US9326962B2 (en) | 2013-10-22 | 2016-05-03 | Steven Hoffman | Compositions and methods for treating intestinal hyperpermeability |
| US10813901B2 (en) | 2013-10-22 | 2020-10-27 | Yamo Pharmaceuticals Llc | Compositions and methods for treating autism |
| US9763903B2 (en) | 2013-10-22 | 2017-09-19 | Steven Hoffman | Compositions and methods for treating intestinal hyperpermeability |
| AU2016247301A1 (en) * | 2015-04-14 | 2017-10-26 | Steven Hoffman | Compositions and methods for treating autism |
| WO2017117158A1 (en) * | 2015-12-28 | 2017-07-06 | Steven Hoffman | Methods of treating amyotrophic lateral sclerosis and symptoms thereof |
| KR102399254B1 (ko) * | 2016-09-28 | 2022-05-17 | 아이거 바이오파마슈티컬스 인코포레이티드 | 비-알코올성 지방간염의 치료를 위한 방법 및 약제학적 조성물 |
| KR102328323B1 (ko) | 2017-03-31 | 2021-11-19 | 엑시얼 테라퓨틱스, 인크. | 자폐증 및 관련 장애의 치료 및 예방을 위한 장-선택적 봉쇄제 |
| KR20190138683A (ko) * | 2017-04-21 | 2019-12-13 | 스티븐 호프만 | 망막병증을 치료하기 위한 조성물 및 방법 |
| EP3431491A1 (en) * | 2017-07-18 | 2019-01-23 | Centre National De La Recherche Scientifique | Methods for purifying proteins having a tubulin carboxypeptidase activity and peptidic based inhibitors thereof |
| KR20200038481A (ko) | 2017-07-19 | 2020-04-13 | 호프만 테크놀로지스, 인크. | 스트레스-관련 장애를 치료하기 위한 조성물 |
| WO2019147934A1 (en) * | 2018-01-29 | 2019-08-01 | Sackner Bernstein Jonathan | Methods for dopamine modulation in human neurologic diseases |
| JP2021530568A (ja) | 2018-07-19 | 2021-11-11 | ヤモ・ファーマシューティカルズ・エルエルシー | 自閉症を処置するための組成物および方法 |
| WO2020018292A1 (en) * | 2018-07-19 | 2020-01-23 | Yamo Pharmaceuticals Llc | Compositions and methods for treating autism |
| WO2020231909A1 (en) * | 2019-05-11 | 2020-11-19 | Steven Hoffman | Compositions and methods for treating bile acid associated diseases |
| EP3968785A4 (en) | 2019-05-14 | 2023-01-11 | Tyme, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER |
| US10905698B1 (en) | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
| WO2024059323A1 (en) * | 2022-09-16 | 2024-03-21 | Halas Francis Peter | Low dose, sustained release formulation for alleviating symptoms caused by increased levels of dopamine and norepinephrine |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999056747A1 (en) * | 1998-05-05 | 1999-11-11 | Jose Pozuelo | Compositions and methods for treating particular chemical addictions and mental illnesses |
| GB201020032D0 (en) * | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
| US9949923B2 (en) * | 2011-03-15 | 2018-04-24 | Optinose As | Nasal delivery |
-
2013
- 2013-10-24 US US14/062,165 patent/US20150111878A1/en not_active Abandoned
-
2014
- 2014-10-21 KR KR1020167013331A patent/KR20160093000A/ko not_active Ceased
- 2014-10-21 MX MX2016004920A patent/MX2016004920A/es unknown
- 2014-10-21 WO PCT/US2014/061590 patent/WO2015061328A2/en not_active Ceased
- 2014-10-21 CA CA2925324A patent/CA2925324A1/en not_active Abandoned
- 2014-10-21 PT PT171762313T patent/PT3238707T/pt unknown
- 2014-10-21 EP EP17176231.3A patent/EP3238707B1/en active Active
- 2014-10-21 DK DK17176231.3T patent/DK3238707T3/da active
- 2014-10-21 ES ES17176231T patent/ES2865505T3/es active Active
- 2014-10-21 EP EP20174728.4A patent/EP3750555A1/en not_active Withdrawn
- 2014-10-21 CN CN202110888794.XA patent/CN113893239A/zh active Pending
- 2014-10-21 EP EP14793397.2A patent/EP3060241A2/en not_active Withdrawn
- 2014-10-21 CN CN201480058279.7A patent/CN105848652A/zh active Pending
- 2014-10-21 JP JP2016522050A patent/JP2016538254A/ja active Pending
- 2014-10-21 AU AU2014340303A patent/AU2014340303B2/en active Active
- 2014-10-21 RS RS20210267A patent/RS61806B1/sr unknown
- 2014-10-21 PL PL17176231T patent/PL3238707T3/pl unknown
-
2016
- 2016-03-22 IL IL244707A patent/IL244707B/en active IP Right Grant
- 2016-03-30 PH PH12016500581A patent/PH12016500581A1/en unknown
-
2019
- 2019-06-27 JP JP2019119837A patent/JP2019203003A/ja active Pending
-
2020
- 2020-02-06 PH PH12020550046A patent/PH12020550046A1/en unknown
- 2020-02-06 PH PH12020550047A patent/PH12020550047A1/en unknown
- 2020-05-03 IL IL274403A patent/IL274403B/en active IP Right Grant
- 2020-05-12 AU AU2020203101A patent/AU2020203101B9/en active Active
- 2020-09-16 JP JP2020155074A patent/JP2021001194A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020203101B9 (en) | Tyrosine hydroxylase inhibitors for treating intestinal hyperpermeability | |
| US11786496B2 (en) | Composition and methods for treating intestinal hyperpermeability | |
| JP2021534185A5 (enExample) | ||
| SG10201909122QA (en) | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | |
| RU2017121277A (ru) | Фармацевтические композиции, содержащие epa и сердечно-сосудистое средство, и способы их применения | |
| NZ743714A (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| SG10201903512SA (en) | Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases | |
| RU2014136394A (ru) | Морфолиноалкилфумаратные соединения, фармацевтические композиции и способы применения | |
| JP2017515854A5 (enExample) | ||
| RU2017121460A (ru) | Производные пиридинкарбоксамида, способ их получения и их фармацевтическое применение | |
| JP2022031813A (ja) | １５－ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法 | |
| DE602005005165D1 (de) | Verfahren zur verbesserung der bioverfügbarkeit von ospemifen | |
| JP2016501248A5 (enExample) | ||
| JP2013538218A5 (enExample) | ||
| JP2014509305A5 (enExample) | ||
| JP2023554524A (ja) | 非アルコール性脂肪性肝炎の治療のための酸素含有構造強化脂肪酸を含む組合せ療法 |